CytoDyn Inc.
For the period ended May 31, 2026. Filed Aug 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Aug 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 16. FORM 10‑K SUMMARY
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: August 31, 2026 | CYTODYN INC. | |
|---|---|---|
| (Registrant) | ||
| By: | /s/ Jacob Lalezari | |
| Jacob Lalezari | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on August 31, 2026.
Principal Executive Officer:
/s/ Jacob Lalezari
Jacob Lalezari
Chief Executive Officer
Principal Financial and Accounting Officer:
/s/ Robert E. Hoffman
Robert E. Hoffman
Chief Financial Officer
Directors
/s/ Tanya Durkee Urbach
Tanya Durkee Urbach, Chair
/s/ Lishomwa C. Ndhlovu
Lishomwa C. Ndhlovu, M.D., Ph.D.
/s/ Karen J. Brunke
Karen J. Brunke, Ph.D.
/s/ Ryan M. Dunlap
Ryan M. Dunlap
/s/ Stephen M. Simes
Stephen M. Simes
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.